Mosala Nezhad Zahra, Poncelet Alain, de Kerchove Laurent, Gianello Pierre, Fervaille Caroline, El Khoury Gebrine
Institute of Experimental and Clinical Research (IREC), Division of Cardiovascular Research (CARD), Université catholique de Louvain, Brussels, Belgium Department of Cardiovascular and Thoracic Surgery, Université catholique de Louvain, Saint-Luc University Hospital, Brussels, Belgium
Institute of Experimental and Clinical Research (IREC), Division of Cardiovascular Research (CARD), Université catholique de Louvain, Brussels, Belgium Department of Cardiovascular and Thoracic Surgery, Université catholique de Louvain, Saint-Luc University Hospital, Brussels, Belgium.
Interact Cardiovasc Thorac Surg. 2016 Jun;22(6):839-50. doi: 10.1093/icvts/ivw020. Epub 2016 Feb 23.
Extracellular matrix (ECM) derived from small intestinal submucosa (SIS) is widely used in clinical applications as a scaffold for tissue repair. Recently, CorMatrix® porcine SIS-ECM (CorMatrix Cardiovascular, Inc., Roswell, GA, USA) has gained popularity for 'next-generation' cardiovascular tissue engineering due to its ease of use, remodelling properties, lack of immunogenicity, absorbability and potential to promote native tissue growth. Here, we provide an overview of the biology of porcine SIS-ECM and systematically review the preclinical and clinical literature on its use in cardiovascular surgery. CorMatrix® has been used in a variety of cardiovascular surgical applications, and since it is the most widely used SIS-ECM, this material is the focus of this review. Since CorMatrix® is a relatively new product for cardiovascular surgery, some clinical and preclinical studies published lack systematic reporting of functional and pathological findings in sufficient numbers of subjects. There are also emerging reports to suggest that, contrary to expectations, an undesirable inflammatory response may occur in CorMatrix® implants in humans and longer-term outcomes at particular sites, such as the heart valves, may be suboptimal. Large-scale clinical studies are needed driven by robust protocols that aim to quantify the pathological process of tissue repair.
源自小肠黏膜下层（SIS）的细胞外基质（ECM）作为组织修复支架在临床应用中被广泛使用。最近，CorMatrix®猪源SIS-ECM（美国佐治亚州罗斯韦尔市的CorMatrix心血管公司）因其使用方便、重塑特性、无免疫原性、可吸收性以及促进天然组织生长的潜力，在“下一代”心血管组织工程中受到青睐。在此，我们概述猪源SIS-ECM的生物学特性，并系统回顾其在心血管外科应用的临床前和临床文献。CorMatrix®已用于多种心血管外科手术，由于它是使用最广泛的SIS-ECM，因此这种材料是本综述的重点。由于CorMatrix®是心血管外科的一种相对新产品，一些已发表的临床和临床前研究缺乏对足够数量受试者的功能和病理结果的系统报告。也有新报告表明，与预期相反，CorMatrix®植入人体时可能会出现不良炎症反应，并且在特定部位（如心脏瓣膜）的长期结果可能不理想。需要由强大方案驱动的大规模临床研究，旨在量化组织修复的病理过程。
